Roche aims to 'underwhelm' on SMA drug price to challenge rivals
Reuters India -

Swiss drugmaker Roche plans to price its oral spinal muscular atrophy drug (SMA) risdiplam aggressively to challenge two of the world's most expensive medicines, Biogen's Spinraza and Novartis's gene therapy Zolgensma.

Read this story at

Loading...

Related Articles